Aurinia Pharmaceuticals Inc. - 8-K Filing
Aurinia Pharmaceuticals completed the acquisition of Kezar Life Sciences on May 8, 2026. The transaction involved a tender offer for all outstanding shares at $6.955 in cash plus one contingent value right (CVR) per share. Approximately 80.24% of shares were tendered by shareholders. (Items: 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed by Aurinia Pharmaceuticals Inc, 9.01 Financial Statements and Exhibits (d) Exhibits)
Tickers: $AUPH